Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
28 nov. 2022 07h30 HE
|
Zynerba Pharmaceuticals, Inc.
Study finds patients with Fragile X who have a highly methylated FMR1 gene that were treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with placebo ...
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
15 nov. 2022 07h30 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
14 nov. 2022 07h30 HE
|
Zynerba Pharmaceuticals, Inc.
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 $55.9 million in cash and cash...
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
02 nov. 2022 07h30 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
17 oct. 2022 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
10 oct. 2022 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
06 oct. 2022 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
29 sept. 2022 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
22 sept. 2022 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium
08 sept. 2022 09h15 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...